Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)

30-Jul-2009 - USA

Amgen andGlaxoSmithKline (GSK) announced a collaboration in which the companies will share commercialization of Amgen’s monoclonal antibody denosumab for Postmenopausal Osteoporosis (PMO) in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will commercialize the drug for PMO and oncology in the United States (U.S.) and Canada and for all oncology indications in Europe and specified markets.

GlaxoSmithKline will register and commercialize denosumab for all indications in countries where Amgen does not currently have a commercial presence, including China, Brazil, India and South Korea. The structure of the collaboration allows Amgen the option of an expanded role in commercialization in both Europe and certain emerging markets in the future.

Financial terms of the partnership include an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. In Europe, Amgen and GlaxoSmithKline will share profits after accounting for expenses associated with the partnership. In emerging markets, GlaxoSmithKline will be responsible for all commercialization expenses and purchase denosumab from Amgen to meet demand.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV - New Trial in Important Patient Subgroup Will Assess Safety and Anti-Viral Activity

NHM scientists discover first-ever mineral-based treatment for widespread disease using the structure of crystals - Based on the structure of cubic zirconium silicate, the innovative treatment opens doors to future mineral-based treatments made possible by cutting-edge museum science

NHM scientists discover first-ever mineral-based treatment for widespread disease using the structure of crystals - Based on the structure of cubic zirconium silicate, the innovative treatment opens doors to future mineral-based treatments made possible by cutting-edge museum science

Applied DNA Sciences Launches DNA Encryption and Authentication Project in Collaboration with Stony Brook University

Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings

Ground-breaking bacteria-killing viruses unite with antibiotics to fight devastating antibiotic-resistant bacteria

Ground-breaking bacteria-killing viruses unite with antibiotics to fight devastating antibiotic-resistant bacteria

Biophage announces development of a new platform designed for the rapid selective capture and enrichment of bacteria

Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

Chemokine Therapeutics Investigator Presents Encouraging Preliminary Results From CTCE-9908 Phase I/II Clinical Trial

25 Leading Healthcare Institutions and Clinical Laboratories to Evaluate tm Bioscience's Test for Respiratory Viruses - Early Access Program to test unique product that can identify 20 respiratory viruses

Biocrea acquires CNS pipeline and PDE inhibitor platform from Biotie Therapies Corp. and announces corporate strategy - New entity will be based in Radebeul, Germany

Oncolytics Biotech Inc. Announces Publication of Preclinical Research on Combination of Antiangiogenic Cancer Therapy

Epratuzumab data from phase IIb EMBLEM study presented at 9th International Congress on Systemic Lupus Erythematosus